Last reviewed · How we verify
Pramipexole IR tablet
Pramipexole IR tablet is a Small molecule drug developed by Boehringer Ingelheim. It is currently FDA-approved. Also known as: MIRAPEX®/SIFROL.
At a glance
| Generic name | Pramipexole IR tablet |
|---|---|
| Also known as | MIRAPEX®/SIFROL |
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study in Patients With Major Depressive Disorder (PHASE2)
- The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa (PHASE4)
- Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers (PHASE1)
- Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers (PHASE1)
- Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers (PHASE1)
- Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers (PHASE1)
- In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers (PHASE1)
- A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pramipexole IR tablet CI brief — competitive landscape report
- Pramipexole IR tablet updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI
Frequently asked questions about Pramipexole IR tablet
What is Pramipexole IR tablet?
Pramipexole IR tablet is a Small molecule drug developed by Boehringer Ingelheim.
Who makes Pramipexole IR tablet?
Pramipexole IR tablet is developed and marketed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).
Is Pramipexole IR tablet also known as anything else?
Pramipexole IR tablet is also known as MIRAPEX®/SIFROL.
What development phase is Pramipexole IR tablet in?
Pramipexole IR tablet is FDA-approved (marketed).
Related
- Manufacturer: Boehringer Ingelheim — full pipeline
- Also known as: MIRAPEX®/SIFROL
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing